117 related articles for article (PubMed ID: 19637086)
1. Maintenance therapy for central nervous system lymphoma with rituximab.
Ney DE; Abrey LE
Leuk Lymphoma; 2009 Sep; 50(9):1548-51. PubMed ID: 19637086
[No Abstract] [Full Text] [Related]
2. Immuno-chemotherapy with a combination of rituximab, methotrexate, pirarubicin and procarbazine for patients with primary CNS lymphoma--a preliminary report.
Yamanaka R; Homma J; Sano M; Tsuchiya N; Yajima N; Shinbo Y; Hasegawa A; Onda K; Tanaka R
Leuk Lymphoma; 2007 May; 48(5):1019-22. PubMed ID: 17487746
[No Abstract] [Full Text] [Related]
3. Current status and future of relapsed primary central nervous system lymphoma (PCNSL).
Tyson RM; Siegal T; Doolittle ND; Lacy C; Kraemer DF; Neutwelt EA
Leuk Lymphoma; 2003 Apr; 44(4):627-33. PubMed ID: 12769339
[TBL] [Abstract][Full Text] [Related]
4. Is there still a need for specific central nervous system directed prophylaxis for diffuse large B-cell lymphoma in the rituximab era?
Cheah CY; Seymour JF
Leuk Lymphoma; 2014 Mar; 55(3):471-3. PubMed ID: 23906017
[No Abstract] [Full Text] [Related]
5. Rituximab monotherapy for patients with recurrent primary CNS lymphoma.
Batchelor TT; Grossman SA; Mikkelsen T; Ye X; Desideri S; Lesser GJ
Neurology; 2011 Mar; 76(10):929-30. PubMed ID: 21383331
[No Abstract] [Full Text] [Related]
6. Treatment of primary central nervous system lymphoma with induction of complement-dependent cytotoxicity by intraventricular administration of autologous-serum-supplemented rituximab.
Takami A; Hayashi T; Kita D; Nishimura R; Asakura H; Nakao S
Cancer Sci; 2006 Jan; 97(1):80-3. PubMed ID: 16367925
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of rituximab treatment in patients with progressive transformation of germinal centers after Hodgkin lymphoma in complete remission post-induction chemotherapy and radiotherapy.
Picardi M; Zeppa P; Ciancia G; Pettinato G; Grimaldi F; Fabbricini R; Mainolfi C; Pane F
Leuk Lymphoma; 2011 Nov; 52(11):2082-9. PubMed ID: 21663508
[TBL] [Abstract][Full Text] [Related]
8. Recurrence of IgG4-related disease following treatment with rituximab.
Murakami J; Matsui S; Ishizawa S; Arita K; Wada A; Miyazono T; Hounoki H; Shinoda K; Taki H; Sugiyama T
Mod Rheumatol; 2013 Nov; 23(6):1226-30. PubMed ID: 22956241
[TBL] [Abstract][Full Text] [Related]
9. [High-dose methotrexate plus hematopoietic stem cell transplantation supplemented by rituximab intrathecal injection for primary central nervous system lymphoma:two cases report and literature review].
Jiang JH; Fang BM; Xu YH
Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):162-3. PubMed ID: 23611227
[No Abstract] [Full Text] [Related]
10. Rituximab maintenance therapy in central nervous system lymphoma?
Murawski N; Pfreundschuh M
Leuk Lymphoma; 2009 Oct; 50(10):1555-6. PubMed ID: 19757314
[No Abstract] [Full Text] [Related]
11. Impact of maintenance rituximab on duration of response in primary central nervous system lymphoma.
Ambady P; Fu R; Szidonya L; Peereboom DM; Doolittle ND; Neuwelt EA
J Neurooncol; 2020 Mar; 147(1):171-176. PubMed ID: 32026432
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment with Rituximab and Bendamustine in a patient with newly diagnosed Waldenström's Macroglobulinemia complicated by Bing-Neel syndrome.
Varettoni M; Marchioni E; Bonfichi M; Picchiecchio A; Arcaini L; Arbasino C; Gotti M; Da Vià M; Delmonte M; Sciarra R; Cazzola M
Am J Hematol; 2015 Aug; 90(8):E152-3. PubMed ID: 25975811
[No Abstract] [Full Text] [Related]
13. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation.
Pettengell R; Schmitz N; Gisselbrecht C; Smith G; Patton WN; Metzner B; Caballero D; Tilly H; Walewski JA; Bence-Bruckler I; To B; Geisler CH; Schots R; Kimby E; Taverna CJ; Kozák T; Dreger P; Uddin R; Ruiz de Elvira C; Goldstone AH
J Clin Oncol; 2013 May; 31(13):1624-30. PubMed ID: 23547078
[TBL] [Abstract][Full Text] [Related]
14. Long-term response to maintenance treatment with rituximab in CD20(+) multiple myeloma.
Ohno H
Leuk Lymphoma; 2010 Nov; 51(11):2144-6. PubMed ID: 20807088
[No Abstract] [Full Text] [Related]
15. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
[TBL] [Abstract][Full Text] [Related]
16. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
[TBL] [Abstract][Full Text] [Related]
17. Primary central nervous system lymphoma with testicular metastasis.
Liu XJ; Zhao JZ; Li G; Ye X; Yan PX
Clin Neurol Neurosurg; 2012 Jan; 114(1):80-3. PubMed ID: 21871714
[No Abstract] [Full Text] [Related]
18. Successful use of intraventricular and intravenous rituximab therapy for refractory primary CNS lymphoma in a child.
Akyuz C; Aydin GB; Cila A; Akalan N; Soylemezoglu F; Cengiz M; Yazici N; Buyukpamukcu M
Leuk Lymphoma; 2007 Jun; 48(6):1253-5. PubMed ID: 17577799
[No Abstract] [Full Text] [Related]
19. Rituximab monotherapy as a first-line treatment for pulmonary mucosa-associated lymphoid tissue lymphoma.
Okamura I; Imai H; Mori K; Ogura K; Isoda A; Mihara K; Matsumoto M; Saito R; Takahashi T; Ikeda T
Int J Hematol; 2015 Jan; 101(1):46-51. PubMed ID: 25378228
[TBL] [Abstract][Full Text] [Related]
20. Management of primary central nervous system lymphoma.
Royer-Perron L; Hoang-Xuan K
Presse Med; 2018; 47(11-12 Pt 2):e213-e244. PubMed ID: 30416008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
